Drug Guide
Citalopram Hydrobromide
Classification
Therapeutic: Antidepressant
Pharmacological: Selective Serotonin Reuptake Inhibitor (SSRI)
FDA Approved Indications
- Major depressive disorder
Mechanism of Action
Citalopram selectively inhibits the reuptake of serotonin in the central nervous system, increasing serotonergic activity in the synaptic cleft.
Dosage and Administration
Adult: Starting dose typically 20 mg once daily; can be increased up to 40 mg/day based on response and tolerability.
Pediatric: Not FDA-approved for pediatric use; data limited.
Geriatric: Start at a lower dose, e.g., 10 mg/day, and titrate as needed, considering increased sensitivity and risk of side effects.
Renal Impairment: Use with caution; consider dose adjustments, especially in severe impairment.
Hepatic Impairment: Use with caution; start at lower doses with careful monitoring.
Pharmacokinetics
Absorption: Well-absorbed orally, with peak plasma levels in approximately 2-4 hours.
Distribution: Widely distributed; volume of distribution approximately 12 L/kg.
Metabolism: Primarily hepatic via CYP2C19, CYP3A4, and CYP2D6 enzymes.
Excretion: Primarily excreted in urine (cholesterols and conjugates), with a smaller amount in feces.
Half Life: Approximately 35 hours, allowing once-daily dosing.
Contraindications
- Concurrent use of Monoamine Oxidase Inhibitors (MAOIs)
- History of hypersensitivity to citalopram
Precautions
- Use cautiously in patients with a history of seizure disorders
- Monitor for increased risk of suicidal thoughts in children, adolescents, and young adults
- Monitor QT interval, especially at higher doses
Adverse Reactions - Common
- Nausea (Common)
- Insomnia (Common)
- Dry mouth (Common)
- Somnolence (Common)
- Increased sweating (Common)
Adverse Reactions - Serious
- QT prolongation (Rare)
- Serotonin syndrome (Rare)
- Suicidal thoughts or behavior (Potentially increased in young populations)
Drug-Drug Interactions
- MAOIs
- Other serotonergic agents (e.g., triptans, SNRI antidepressants)
- CYP450 inhibitors and inducers
Drug-Food Interactions
- Alcohol (may increase CNS depression and interfere with medication)
- Foods affecting CYP enzymes
Drug-Herb Interactions
- St. John's Wort (risk of serotonin syndrome)
Nursing Implications
Assessment: Monitor mood, suicidal thoughts, and side effects; baseline ECG if at risk for QT prolongation.
Diagnoses:
- Risk for decreased cardiac output related to QT prolongation
- Risk for injury related to somnolence or dizziness
Implementation: Administer with food if GI upset occurs; monitor for therapeutic response and adverse effects.
Evaluation: Assess improvement in depressive symptoms; monitor for adverse effects, including cardiac issues.
Patient/Family Teaching
- Take medication exactly as prescribed; do not double doses.
- Report any signs of unusual bleeding, agitation, or suicidal thoughts.
- Avoid alcohol and other central nervous system depressants.
- Be aware of potential side effects like nausea, sleep disturbances, or dry mouth.
- Schedule regular follow-ups for efficacy and safety monitoring.
Special Considerations
Black Box Warnings:
- Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults
Genetic Factors: Variations in CYP2C19 genotype can affect metabolism and plasma levels.
Lab Test Interference: May slightly elevate liver enzymes; routine monitoring recommended in long-term therapy.
Overdose Management
Signs/Symptoms: Nausea, vomiting, dizziness, tremor, arrhythmias, seizures.
Treatment: Supportive care, activated charcoal if within a few hours of ingestion, cardiac monitoring, and symptomatic treatment.
Storage and Handling
Storage: Store at room temperature away from light and moisture.
Stability: Stable for at least 2 years if stored properly.